OUR FUNDING SEARCH CONTINUES
As expected, we're still working to find funding to help us recover
from the death of a major funder a few months ago. We need leads for
major donors or grants AND the contributions of visitors, as Erowid
is primarily supported by small individual donations.
Thank you to the active community at Reddit.com/r/Drugs, who came
together to donate $1711 after the last Erowid Monthly
We've received several useful suggestions for individuals and
organizations to approach about contributing towards our mission,
but we still need more brainstorming and ideas from Erowid
supporters. (email@example.com or Erowid.org/donations
Thanks to everyone for their continued support!
Earth & Fire
Co-founders, Erowid Center
Well-known conservative televangelist Pat Robertson has stepped
forward to support the legalization of cannabis, stating that the
U.S. has gone overboard with its tough-on-crime stance.
On a related note, there has been additional action on five synthetic
cannabinoids that were temporarily placed into Schedule I a year ago.
The temporary scheduling, which expired at the end of February, has
been extended until August 29. The DEA has also formally proposed
that these chemicals be permanently scheduled. Interested parties may
Erowid has been without an internal search engine for more than two
years, due to no-longer-supported software among other issues. Since
the major search services increasingly cross-index and aggregate user
data across sites, an internal engine is important for the privacy of
our visitors. Using Solr-Lucene and Sperowider, JL has wrangled our
new search engine into working order, and with feedback from users,
it will continue to be improved over upcoming months.
Published from 1991 through 1996, the zine Pills-a-go-go covered
pharmaceuticals, vitamins, amino acids, and other pill-related
topics, often focusing on their recreational uses. Erowid has
recently archived all but two of the 23 issues of this publication.
The topics covered in counterculture author Jim Hogshire's writings
have ranged from facing prison time to growing opium poppies. His
zine and book Pills-a-go-go featured "a cultural study of
pills". Learn more about him in this new character vault.
While less commonly reported than PMA, PMMA's presence in ecstasy
tablets and "legal high" products, as well as the length of time it
takes to come on, may lead to some people redosing and unknowingly
risking an overdose.
In the early morning hours of March 2, 2012 psychedelic researcher
Gary Fisher passed away peacefully. Fisher was a psychologist who
did pioneering work in the late 1950s and early 1960s treating
children suffering from schizophrenia and autism by administering LSD
or psilocybin. Since its creation last year, Fisher's character
vault has remained one of the "top twenty" most-visited on Erowid.
We recently added more content to his vault, including some
rare documents scanned from the Stolaroff Collection.
An updated list of links for state statutes related to the scheduling
of phenethylamine psychedelics. First published in The Shulgin Index,
which is currently being prepared for its second printing.
After a recent paper showing sildenafil (Viagra) blocked neurotoxic
effects of high doses of MDMA in rats, we updated this page with a
new section about the research. We don't have many experience reports
for this combination, so if you know someone who has taken the two
together, encourage them to submit a report.
Erowid is frequently mentioned in articles and books. These mentions
may be reviews, recommendations or the use of Erowid as a reference.
EcstasyData is a project of Erowid Center that conducts laboratory
testing of street Ecstasy tablets and publishes these and other test
If you find Erowid a useful resource and are interested in supporting
its future development, please consider donating or becoming a member.
Donations to Erowid Center are tax-deductible in the United States.
- To UNSUBSCRIBE - send an empty email to: firstname.lastname@example.org
- To SUBSCRIBE - send an empty email to: email@example.com